The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be availa...
- Colitis, Ulcerative
- Inflammatory Bowel Diseases
- Crohn Disease
- Pediatric ulcerative colitis
- Pediatric Crohn's disease
Age: 2 - 19 years
Gender: All